Navigation Links
Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
Date:4/18/2012

BANNOCKBURN, Ill., April 18, 2012 /PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries.  

Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer.  Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities.

Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer.  Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.

About Pinnacle Biologics

Pinnacle Biologics Inc., a privately held bio-pharmaceutical company, specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. The company is based in the U.S.A with its headquarters in Bannockburn, Illinois; and its European subsidiary, Pinnacle Biologics BV,is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About Bioprojet Pharma

Bioprojet Pharma is a privately held European pharmaceutical company with is headquarters in Paris, France.  Bioprojet is a leading European research based specialty pharmaceutical company involved in the design and development of compounds from pre-clinical to Phase III.  The company markets pharmaceutical products across Europe.

Contact Information:
Pinnacle Biologics Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695
www.pinnaclebiologics.com


'/>"/>
SOURCE Pinnacle Biologics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago
2. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
3. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
4. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
5. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
8. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
9. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):